Akhil Abraham Saji, MD
Akhil Abraham Saji, MD, is a urologist specializing in minimally invasive surgery and urologic oncology with an interest in technology-driven innovation within health care.
Articles by Akhil Abraham Saji, MD
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Increasing competition in robot-assisted surgical platform production will increase accessibility for patients everywhere.
PSMA PET imaging is a leap forward in the fight to cure prostate cancer, especially as theranostic capabilities expand.
What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI?
One might assume that the AUA meeting is geared toward practicing urologists, but it is also crucial for urologic trainees.
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents.
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
This review highlights the existing research regarding the financial toxicity of advanced prostate cancer.
This review highlights the upcoming plenary sessions of importance in prostate, bladder, kidney, and testicular cancer.
AUA guidelines for localized RCC have thermal ablation as an alternative modality. EAU guidelines are conflicting.
Mutahar Ahmed, MD, discusses the history and current applications of single-port robotic surgery in prostate cancer.
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
A review of the GÖTEBORG-2 trial and the current recommendations for utilizing mpMRI in prostate cancer screening, ...
An investigation and review of both studies regarding their differences, similarities, and conclusions.
The evidence regarding bisphosphate and denosumab therapy and the impact that bone-protective agents can have on patients.
At the ASTRO 2022 meeting, several authors presented abstracts on postprostatectomy radiation that are worth reviewing.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.